AWH.N
Latest Trade
6.71USDChange
0.07(+1.05%)Volume
15,580Today's Range
-
6.7252 Week Range
-
10.47As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 6.64 |
---|---|
Open | 6.58 |
Volume | 15,580 |
3M AVG Volume | 16.78 |
Today's High | 6.72 |
Today's Low | 5.62 |
52 Week High | 10.47 |
52 Week Low | 0.62 |
Shares Out (MIL) | 111.56 |
Market Cap (MIL) | 749.13 |
Forward P/E | -41.97 |
Dividend (Yield %) | -- |
Aspira Women’s Health Inc Announces Pricing Of $45 Million Public Offering Of Common Stock
Aspira Women's Health Inc. Announces Proposed Public Offering Of Common Stock
Aspira Women's Health Inc Files For Mixed Shelf Of Upto $100 Million
Aspira Women’s Health Inc., formerly Vermillion, Inc., is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1, Overa and OVA1PLUS risk of malignancy tests for ovarian cancer. The Company also sells a product for genetic testing for specific women’s health diseases, called ASPiRA GenetiX, with a core focus on ovarian cancer. OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor before planned surgery. The Overa is a second-generation biomarker panel intended to maintain its product’s sensitivity while improving specificity. OVA1PLUS is a service offering combining its OVA1 and Overa products, designed to enhance accuracy and reduce false elevations in the intermediate-risk area.
Industry
Biotechnology & Drugs
Contact Info
Suite 100
12117 Bee Caves Road Building Three
AUSTIN, TX
78738
United States
+1.512.5190400
http://www.vermillion.comExecutive Leadership
James T. LaFrance
Independent Chairman of the Board
Valerie Barber Palmieri
President, Chief Executive Officer, Director
Robert Harry Beechey
Chief Financial Officer
Sandra E. Brooks
Independent Director
Nancy G. Cocozza
Independent Director
Price To Earnings (TTM) | -- |
---|---|
Price To Sales (TTM) | 165.99 |
Price To Book (MRQ) | 48.02 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 14.80 |
LT Debt To Equity (MRQ) | 11.53 |
Return on Investment (TTM) | -102.62 |
Return on Equity (TTM) | -80.49 |
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.